PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “SHIKIMIC ACID”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 595 records · Page 33Linked to original sources
PubMed1992

Synthesis and cytotoxicity of shikimate analogues. Structure:activity studies based on 1-crotonyloxymethyl-3R,4R,5R-trihydroxycyclohex-2-enone.

Syntheses are described for and structure:activity studies undertaken of the anti-tumour activity of (2-crotonyloxymethyl-(4R,5R,6R)-4,5,6-trihydroxycyclohex-2-+ ++enone) (1) and its analogues 1-crotonyloxymethyl-(3R,4S,5R)-3,4,5-trihydroxycyclohex-1-en e (3), 1-crotonyloxymethyl-(3R,4S,5S)-3,4,5-trihydroxycyclohexene (4) and 2-crotonyloxymethyl-2-cyclohexenone (5), which differ from 1 in the presence/absence of the cyclic keto group and/or the stereochemistry at one of the -OH bearing carbon atoms. None of the above compounds, including 1, directly inhibited glyoxalase I, isolated for the first time to homogeneity from rat Yoshida sarcomas and for which a purification protocol was developed. The apparent inhibition of glyoxalase I by 1 and 5 (but not detected for 4 or 3) could be explained by reaction of 1 and 5 with the glutathione present in the assay buffer and the consequent depletion of substrate. 1 and 5 were found to react readily with glutathione whereas 4 and 3 did not react. In vitro chemosensitivity studies against a panel of tumour cell lines of both mouse and human origin showed that in parallel with their thiol reactivity, 1 and 5 exhibited significant in vitro cytotoxicity whereas 4 and 3 did not. Concentrations of drug required to cause 50% cell kill (ID50 values) were in the range 0.5-19 microM (0.1-2.8 micrograms/ml) for 5, and 3-44 microM (0.7-10 micrograms/ml) for 1. The structural features causing the differences in antitumour effects were localized on this basis to the alpha,beta-unsaturated ketone linkage as opposed to the stereochemistry of the (trihydroxy) alcoholic sites.

Animals↗
PubMed1990

"Kinetic competence" of the 5-enolpyruvoylshikimate-3-phosphate synthase tetrahedral intermediate.

The tetrahedral intermediate formed at the active site of 5-enolpyruvoylshikimate-3-phosphate synthase by reaction of shikimate 3-phosphate with phosphoenolpyruvate was isolated, and its properties in solution and in reaction with enzyme were examined. The intermediate was moderately stable at pH 7.0, with a half-life of 45 min, and showed increasing lifetimes with increasing pH (t1/2 greater than 48 h at pH greater than or equal to 12). The intermediate bound to the enzyme rapidly, with a second order rate constant of 5 x 10(7) M-1 s-1. Upon binding to the enzyme, it reacted to form both products (5-enolpyruvoylshikimate 3-phosphate, Pi) and substrates (shikimate 3-phosphate, phosphoenolpyruvate) in proportions predicted by the rate constants defined previously for reactions occurring at the active enzyme site (Anderson, K.S. Sikorski, J.A., and Johnson, K. A. (1988b) Biochemistry 27, 7395-7406). The kinetics of binding and dissociation of stable phosphonate analogs of the tetrahedral intermediate (Alberg, D., and Bartlett, P.A. (1989) J. Am. Chem. Soc. 111, 2337) were also examined. In comparison to the intermediate, the analogs bound to the enzyme 300-10,000 fold more slowly and at least 300-20,000 times mroe weakly. These results clarify the definitions for kinetic competence of enzyme intermediates and call into question the significance of the slow binding of analogs of transition states or enzyme intermediates.

3-Phosphoshikimate 1-Carboxyvinyltransferase↗